All In Biotech

Drug Trial Radar · NCT07727629

Safety, PK, and PD Comparison of UI059 and UIC202201 in Healthy Volunteers

A Randomized, Open-label, Multiple-dose, Crossover Phase 1 Clinical Trial to Compare and Evaluate the Safety, Pharmacokinetics and Pharmacodynamics Characteristics After Oral Administration of UI059 and UIC202201 in Healthy Adult Volunteers

Last checked: Nov 20, 2026Latest source record: Jul 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 2026

Primary completion

Aug 2026

Study completion Aug 2026

Sponsor

Lead sponsor
Korea United Pharm. Inc.Industry
Sponsor type
Industry
First posted
Jul 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A randomized, open-label, multiple-dose, crossover phase 1 clinical trial to compare and evaluate the safety, pharmacokinetics and pharmacodynamics characteristics after oral administration of UI059 and UIC202201 in healthy adult volunteers

Conditions

  • Gastro Esophageal Reflux Disorder

Interventions

  • UI059Drug

    take UI059 once a day for 7 days

  • UIC202201Drug

    take UIC202201 once a day for 7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUCτ,ssTime frame: day1: 0-24 hours / day 5, day 6: 0 hour / day 7: 0-24 hours
  2. Percent decrease from baseline in integrated gastric acidityTime frame: Day -1(0 hour) - Day 1(0 hour) / Day1(0 hour) - Day2(0 hour) / Day7(0 hour) - Day7(24 hour)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chungbuk national university hospital

    Cheongju-si, North Chungcheong, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.